Human infection with Sporolactobacillus laevolacticus, Marseille, France.
In March 2015, a 47-year-old man with no underlying disease was admitted to the emergency unit of the North Hospital in Marseille, France. He had an infected wound on his right foot that occurred after he jogged barefoot during a vacation in Comoros, but the patient did not know how he obtained the wound and had not taken any antiinflammatory drugs. The foot became swollen, red, hot, and painful. He visited a doctor during his vacation and was prescribed antiinflammatory drugs and antimicrobial drugs, including a second-generation cephalosporin and ofloxacin.
The patient returned to Marseille, but the infection persisted. At admission, the patient was apyretic but had high levels of C-reactive protein (85.7 mg/L [reference range 1-3 mg/L]) and fibrinogen (8.35 g/L), which indicated inflammation. His leukocyte count was normal (9.29 x [10.sup.9] cells/L) but his procalcitonin level (0.19 [micro]g/L) was increased, which suggested that the infection had not been cured. A cellulitis abscess was suspected, and surgical cleaning and drainage was performed on March 10 (Figure, panels A, B).
Samples were collected during surgery and probabilistic antimicrobial drug therapy, including tazocillin, clindamycin, and vancomycin, was initiated. Abscess puncture liquid collected during surgery was sterile when incubated directly on Columbia and Polyvitex agar plates (bioMerieux, Craponne, France). However, a surgical sample inoculated into a blood culture bottle grew gram-positive bacilli after 4 days.
Subculture colonies were identified by using matrix-assisted laser desorption/ionization time of flight (MALDITOF) mass spectrometry (Bruker, Leipzig, Germany) as S. laevolaticus (score 1.88). Identification was confirmed by PCR amplification of the 16S RNA gene (3). A 944-bp sequence showed 99.5% similarity with that of a known S. laevolaticus strain (GenBank accession no. AB362648) by BLAST analysis (http://www.ncbi.nlm.nih.gov).
The S. laevolaticus strain was susceptible to amoxicillin, amoxicillin/clavulanate, imipenem, metronidazole, clindamycin, and vancomycin. The antimicrobial drug regimen was then changed to clindamycin and trimethoprim/sulfamethoxazole, and the patient showed an excellent clinical outcome. The patient was considered clinically cured 7 weeks later (Figure, panel C).
S. laevolacticus has been studied for its capacity to survive extreme conditions and for its fermentation system (4-8). The fact that the bacterium has not been previously isolated from humans might be because it was isolated only from plant rhizospheres (2), so human studies have not been conducted. In addition, conventional identification methods, such as the VITEK 2 system (bioMerieux) or the API system (bioMerieux), cannot identify S. laevolacticus. Since September 2009, we have used MALDI-TOF mass spectrometry in North Hospital for routine identification of bacterial species isolated from clinical samples (P). This strategy increases our capacity to detect rare bacterial species, including emerging pathogens (10).
The bacterial species was accurately identified by using MALDI-TOF and then confirmed by using a 16S RNA PCR. Because the bacterium was originally isolated from a plant rhizosphere and the patient was hospitalized with an open wound in the foot and bacteremia, we speculate that the infection was the direct result of close extended contact between the wound and soil infected with the bacteria. This case confirms that S. laevolaticus can be responsible for human infections and suggests that this bacterial species could be an emerging opportunistic pathogen responsible for human infections.
We thank TradOnline (http://www.tradonline.fr/en/) for providing English corrections.
This study was partly supported by the Centre National de la Recherche Scientifique and the Institut Hospitalo-Universitaire Mediterranee Infection.
(1.) Andersch I, Pianka S, Fritze D, Claus D. Description of Bacillus laevolacticus (ex Nakayama and Yanoshi 1967) sp. nov., nom. rev. Int J Syst Bacteriol. 1994;44:659-64. http://dx.doi.org/10.1099/00207713-44-4-659
(2.) Nakayama O, Yanoshi M. Spore-bearing lactic acid bacteria isolated from rhizosphere I. Taxonomic studies on Bacillus laevolacticus nov. sp. and Bacillus racemilacticus nov. sp.
J Gen Appl Microbiol. 1967;13:139-53. http://dx.doi.org/10.2323/jgam.13.139
(3.) Morel A-S, Dubourg G, Prudent E, Edouard S, Gouriet F, Casalta J-P, et al. Complementarity between targeted real-time specific PCR and conventional broad-range 16S rDNA PCR in the syndrome-driven diagnosis of infectious diseases. Eur J Clin Microbiol Infect Dis. 2015;34:561-70. http://dx.doi.org/10.1007/s10096-014-2263-z
(4.) Mowlick S, Inoue T, Takehara T, Kaku N, Ueki K, Ueki A. Changes and recovery of soil bacterial communities influenced by biological soil disinfestation as compared with chloropicrin- treatment. AMB Express. 2013;3:46. http://dx.doi.org/10.1186/ 2191-0855-3-46
(5.) Sawai H, Na K, Sasaki N, Mimitsuka T, Minegishi S, Henmi M, et al. Membrane-integrated fermentation system for improving the optical purity of D-lactic acid produced during continuous fermentation. Biosci Biotechnol Biochem. 2011;75:2326-32. http://dx.doi.org/10.1271/bbb.110486
(6.) Li Y, Wang L, Ju J, Yu B, Ma Y. Efficient production of polymer-grade d-lactate by Sporolactobacillus laevolacticus DSM442 with agricultural waste cottonseed as the sole nitrogen source. Bioresour Technol. 2013;142:186-91. http://dx.doi.org/10.1016/j.biortech.2013.04.124
(7.) Gulati HK, Chadha BS, Saini HS. Production and characterization of thermostable alkaline phytase from Bacillus laevolacticus isolated from rhizosphere soil. J Ind Microbiol Biotechnol. 2007;34:91-8. http://dx.doi.org/10.1007/s10295-006-0171-7
(8.) Wang H, Wang L, Ju J, Yu B, Ma Y. Genome sequence of Sporolactobacillus laevolacticus DSM442, an efficient polymer-grade D-lactate producer from agricultural waste cottonseed as a nitrogen source. Genome Announc. 2013;1:e01100-13.
(9.) Seng P, Drancourt M, Gouriet F, La Scola B, Fournier P-E, Rolain JM, et al. Ongoing revolution in bacteriology: routine identification of bacteria by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Clin Infect Dis. 2009; 49:543-51. http://dx.doi.org/10.1086/600885
(10.) Seng P, Abat C, Rolain JM, Colson P, Lagier J-C, Gouriet F, et al. Identification of rare pathogenic bacteria in a clinical microbiology laboratory: impact of matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol. 2013;51:2182-94. http://dx.doi.org/10.1128/JCM.00492-13
Address for correspondence: Jean-Marc Rolain, Unite de Recherche. sur les Maladies Infectieuses Tropicales Emergentes, UM 63, Centre National de la Recherche Scientifique 7278, Institut de Recherche pour le Developpement 198, Institut National de la Sante et de la Recherche Medicale Unite 1095, Institut Hospitalo-Universitaire Mediterranee Infection, Faculte de Medecine et de Pharmacie, Aix-Marseille Universite, 27 Blvd Jean Moulin, 13385 Marseille CEDEX 05, France; email: firstname.lastname@example.org
Cedric Abat,  Jad Kerbaj,  Gregory Dubourg, Vincent Garcia, Jean-Marc Rolain
Author affiliation: Aix-Marseille Universite, Marseille, France
 These authors contributed equally to this article.
|Printer friendly Cite/link Email Feedback|
|Author:||Abat, Cedric; Kerbaj, Jad; Dubourg, Gregory; Garcia, Vincent; Rolain, Jean-Marc|
|Publication:||Emerging Infectious Diseases|
|Article Type:||Letter to the editor|
|Date:||Nov 1, 2015|
|Previous Article:||Multidrug-resistant tuberculosis in child successfully treated with 9-month drug regimen.|
|Next Article:||The Fantastic Laboratory of Dr. Weigl: How Two Brave Scientists Battled Typhus and Sabotaged the Nazis.|